Futibatinib

COMPOSITION:

Each film-coated tablet contains Futibatinib……………4mg.

INDICATION:

LuciFutib is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.

DOSAGE AND USE:

• Confirm the presence of an FGFR2 gene fusion or other rearrangement prior to initiation of treatment with LuciFutib.

• Recommended dose is 20 mg orally (five 4 mg tablets) once daily until disease progression or unacceptable toxicity occurs.

• Swallow tablet whole, with or without food.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciFutib during Pregnancy and Lactation.